Idexx Laboratories Rebate and up-front considerations arrangements — Deferred Revenue increased by 0.6% to $35.50M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 18.3%, from $30.00M to $35.50M. This is a positive signal — higher values indicate stronger performance for this metric.
An increase indicates growing deferred revenue from customer contracts, signaling future revenue recognition potential, while a decrease may indicate faster fulfillment or lower new contract volume.
This metric quantifies the total amount of consideration received from customers for rebate and up-front arrangements th...
Similar to contract liabilities or deferred revenue balances reported by peers in the healthcare diagnostics and equipment sector.
idxx_segment_rebate_and_up_front_considerations_arrangements_deferred_revenue| Q4 '22 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $36.10M | $32.90M | $31.90M | $30.40M | $29.80M | $30.00M | $30.00M | $35.10M | $34.60M | $35.30M | $35.50M |
| QoQ Change | — | -8.9% | -3.0% | -4.7% | -2.0% | +0.7% | +0.0% | +17.0% | -1.4% | +2.0% | +0.6% |
| YoY Change | — | -8.9% | — | — | — | -8.8% | -6.0% | +15.5% | +16.1% | +17.7% | +18.3% |